HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Araga, S. Articles by Nakashima, K. Search for Related Content PubMed PubMed Citation Articles by Araga, S. Articles by Nakashima, K.

A Complementary Peptide Vaccine That Induces T Cell Anergy and Prevents Experimental Allergic Neuritis in Lewis Rats¹

Division of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, Japan

We have developed and described a new method of altering T cell-mediated autoimmune diseases by immunization with the complementary peptide against T cell epitopes. The complementary peptide (denoted NAE 07-06) to the bovine P2 protein, residues 60–70 (denoted EAN 60–70), was tested in the Lewis rat model of experimental allergic neuritis (EAN). Immunization with NAE 07-06 induced polyclonal and monoclonal Abs that inhibited the proliferation of the P2-specific T cell line, stimulated with EAN 60–70, and recognized Vß, but not V, of TCRs. Proliferation of T cells treated with anti-NAE 07-06 Abs could be partially restored by treatment with rIL-2, in accordance with an anergy model. A homologous sequence was found between NAE 07-06 and the VDJ junction of the TCR ß-chain from an EAN 60–70-specific T cell line. Rats preimmunized with NAE 07-06 in vivo before EAN induction showed less disease severity clinically and histologically. These data suggest a new therapeutic approach for T cell-mediated autoimmune disorders through the induction of anti-TCR Abs with complementary peptide Ags.

This article has been cited by other articles:

				J. L. McAnally, L. Xu, M. Villain, and J. E. Blalock The Role of Adjuvants in the Efficacy of a Peptide Vaccine for Myasthenia Gravis Experimental Biology and Medicine, April 1, 2001; 226(4): 307 - 311. [Abstract] [Full Text]

				S. ARAGA, L. XU, K. NAKASHIMA, M. VILLAIN, and J. E. BLALOCK A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help FASEB J, January 1, 2000; 14(1): 185 - 196. [Abstract] [Full Text]